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Abstract
Vc9Vd2 cells are cytotoxic T cells that are able to recognize epithelial ovarian carcinoma (EOC) cells. Therefore, Vc9Vd2 cell-
based adoptive transfer is an attractive therapy for EOC. However, the inefficient ex vivo expansion after specific stimulation
of Vc9Vd2 cells from some patients and the relationships between Vc9Vd2 cells and clinical course of EOC are issues that
remain to be clarified. Herein, peripheral blood mononuclear cells (PBMCs) from 60 EOC patients were stimulated with
bromohydrin pyrophosphate (BrHPP) or zoledronate, which are specific agonists of Vc9Vd2 cells. The compounds differed in
their efficacies to induce ex vivo Vc9Vd2 PBMC expansion, but 16/60 samples remained inefficiently expanded with both
stimuli. Interestingly, the Vc9Vd2 cells in these low-responding PBMCs displayed before expansion (ex vivo PBMCs) an
altered production of the pro-inflammatory cytokines IFN-c and TNF-a, a decreased naive fraction and a reduced frequency.
No evidence of an involvement of CD4+CD25+Foxp3+ regulatory cells was observed. Importantly, our data also demonstrate
that a Vc9Vd2 cell frequency of 0.35% or less in EOC PBMCs could be used to predict low responses to both BrHPP and
zoledronate. Moreover, our data highlight that such a deficiency is not correlated with advanced EOC stages but is
associated with more refractory states to platinum-based chemotherapy and is an independent predictor of shorter disease-
free survival after treatment. These results are the first to suggest a potential contribution of Vc9Vd2 cells to the anti-tumor
effects of chemotherapeutic agents and they strengthen interest in strategies that might increase Vc9Vd2 cells in cancer
patients.
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Introduction
Human Vc9Vd2 cells are a predominant subset of peripheral
blood cd T cells that express a unique TCR with Vc9-Vd2
regions. These cells, which usually represent 0.5–10% of the
peripheral lymphoid pool, react against various tumor cells
through the recognition of phosphorylated isoprenoid derivatives
defined as phosphoantigens [1,2]. Vc9Vd2 cells can directly kill
their targets and release pro-inflammatory cytokines that boost
the anti-tumor effector cells of the adaptive immune system [3].
Due to these characteristics, the selective triggering of these cells
could be of major interest in cancer immunotherapy [4].
Several currently available clinical-grade compounds are able to
strongly activate Vc9Vd2 cells and, with IL-2, can induce the
selective outgrowth of these cells in vitro and in vivo. These
compounds are either synthetic phosphoantigens, such as
bromohydrin pyrophosphate (BrHPP, PhosphostimTM), or
pharmacological inhibitors of the mevalonate pathway, such as
the aminobisphosphonates (i.e., zoledronate, ZometaTM). Such
compounds have been recently assessed in passive or active
immunotherapeutic trials in patients with hematological malig-
nancies or solid tumors [5–14]. These treatments have been
generally well tolerated and have induced encouraging objective
responses in some patients [12,15,16].
Epithelial ovarian cancer (EOC) is the fifth most frequently
occurring cancer in women and causes more deaths than any
other gynecologic cancer. Most EOC patients are diagnosed at
an advanced stage. Currently, all patients undergo surgical
procedures, and 90% of patients also receive a platinum-based
chemotherapy. However, the 5-year survival rate remains below
40%. Therefore, the increasing knowledge about the role of
immunosurveillance in EOC has led to the exploration of
innovative therapeutic strategies that target the immune system
[17]. Recently, our group demonstrated that in vitro phosphoan-
tigen-expanded Vc9Vd2 cells from EOC patients display high
cytolytic activity against fresh ovarian autologous tumor cells,
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thus providing a rational for Vc9Vd2 cell-based adoptive
transfer in EOC patients [18]. However, the relationships
between Vc9Vd2 cells and progression or clinical outcomes of
EOC remain unexplored. Additionally, some concerns exist
about the efficacy of Vc9Vd2 cell expansions with conventional
protocols that are based on the ex vivo stimulation of peripheral
blood mononuclear cells (PBMCs) with a single dose of either
BrHPP or zoledronate and culture conditions that require IL-2.
These protocols are suitable for cells from healthy donors
[19,20]. However, they failed to efficiently expand the Vc9Vd2
cells from some EOC patients [18], similar to observations in
other cancers [12,14,20–22]. It remains to be seen whether
these failures in some EOC patients are related to intrinsic
differences in the Vc9Vd2 cells or are due to differences in
other environmental parameters. An understanding of such
differences would help to optimize future clinical trials of
Vc9Vd2 cell-based adoptive transfer therapies in EOC.
In this study, we investigated the following in a cohort of 60
EOC patients: the parameters associated with inefficient BrHPP-
and zoledronate-induced Vc9Vd2 cell expansions and the
possibility of an association between the presence of Vc9Vd2
cells and the clinical course of EOC. We report that PBMCs that
were inefficiently expanded with BrHPP and with zoledronate
have before expansion (ex vivo PBMCs) reduced frequencies of
Vc9Vd2 cells and that these cells display alterations in their
phenotype and functionality. In addition, we reveal that a Vc9Vd2
cell frequency of 0.35% or less in ex vivo EOC PBMCs predicts low
responses to both BrHPP- and zoledronate-based stimulation
protocols and that such a cellular deficiency is related to the
clinical progression and recurrence of EOC after chemotherapy-
based treatment.
Results
The Expansions of Vc9Vd2 PBMCs in Response to BrHPP
and to Zoledronate are Lower in EOC Patients than in
Healthy Donors
First, we compared the expansions of PBMCs from 60 EOC
patients (EOC PBMCs) and from 13 healthy female donors after a
specific Vc9Vd2 cell stimulation with a single dose of either
BrHPP or zoledronate (Zol), which were relevant to clinical trial
protocols, and a culture for two weeks in presence of IL-2 (Fig. 1).
The median frequency of Vc9Vd2 cells in expanded PBMCs
(Fig. 1A) and the median number of expanded Vc9Vd2 cells
(Fig. 1B) were significantly lower in EOC patients than in donors
at 14 days post-stimulation with either BrHPP or Zol. These data
confirm that the responses of Vc9Vd2 PBMCs to both stimulation
protocols are significantly reduced in EOC patients.
BrHPP and Zoledronate Differ in their Capacities to
Expand Vc9Vd2 PBMCs from EOC Patients
Taking into account our results from EOC patient PBMC
expansions (Fig. 1) and the minimal rate of purity that was
previously defined for a Vc9Vd2 cell-based therapy product
[6,23], we selected the expanded Vc9Vd2 cell number of 26106
cells (generated from 16106 PBMCs) (see Table 1 legend for
details) and the Vc9Vd2 cell frequency of 70% among the
expanded cells as cut-off values to distinguish efficient expansions
($26106 cells and $70% ) from inefficient expansions (,26106
cells or ,70%). Four statistically distinct groups of samples were
thus identified in our experimental conditions (Table 1): the
responding PBMCs (R) that were efficiently expanded with both
stimuli (53%); the BrHPP-low-responding PBMCs (Br-LR) that
were only efficiently expanded with Zol (13%); the Zol-low-
responding PBMCs (Zol-LR) that were only efficiently expanded
with BrHPP (7%); and the low-responding PBMCs (LR) that were
inefficiently expanded regardless of the stimulus applied (27%).
These data reveal the distinct abilities of conventional BrHPP- and
zoledronate-based protocols to efficiently expand Vc9Vd2 PBMCs
from EOC patients.
The Capacities of Vc9Vd2 Cells to Proliferate and to
Produce the Pro-inflammatory Cytokines IFN-c and TNF-a
are Reduced in LR EOC PBMCs
To investigate the parameters associated with the low-response
status of Vc9Vd2 PBMCs to both BrHPP- and zoledronate-based
stimulation protocols, comparative analyses were restricted to the
LR and R groups.
We first compared the fold increases of Vc9Vd2 PBMCs 14
days after BrHPP or Zol stimulation (Fig. 2A and 2B). The fold
increases were significantly lower in the LR PBMCs than in the R
PBMCs after treatment with either agonist (Fig. 2A). The median
BrHPP-induced Vc9Vd2 cell fold increase was 812 [352–2333]
for the R group and only 132 [74–609] for the LR group (Fig. 2A).
A similar trend was observed in Zol-treated cells, with median fold
increases of 712 [339–1854] for the R group and 403 [140–872]
for the LR group (Fig. 2B). The production of the pro-
inflammatory cytokines IFN-c and TNF-a byVc9Vd2 cells in
LR and R EOC PBMCs before expansion (ex vivo PBMCs) was
also addressed with intracellular staining. Experiments were
performed by stimulating ex vivo PBMCs with BrHPP or PMA/
Ionomycin. Due to few PBMC amounts in samples coming from
patients, zoledronate was skipped from the following activation
assays. The productions of TNF-a and IFN-c were found to be
significantly reduced in LR PBMCs as compared to R PBMCs
(Fig. 2C and 2D). Importantly, doses of BrHPP that were
saturating for R PBMCs failed to restore the IFN-c and TNF-a
responses in LR PBMCs (Fig. S1). All together, these results
demonstrate an altered functional profile of Vc9Vd2 cells in LR
EOC PBMCs.
The reduced proliferation and cytokine production of Vc9Vd2
cells could result from various factors including a reduced
expression of T-cell receptor CD3f chains, altered proportions
of naive and memory subsets or an unfavorable ratio of regulatory
T cells to Vc9Vd2 cells. These possibilities were subsequently
investigated.
The Expression Level of CD3f Chains is Similar between
the ex vivo LR and R EOC PBMCs
The activation signal transduction of T lymphocytes passes
through the cytoplasmic tails of the T-cell receptor CD3f chains.
A defect in the expression of these components on ex vivo Vc9Vd2
cells from LR PBMCs was explored. However, no significant
differences were detected in the percentages and levels (MFI) of
CD3f chain expression between ex vivo LR and R Vc9Vd2
PBMCs (Fig. 2E). We also compared the abilities of Vc9Vd2 cells
in LR and R EOC PBMCS to express the class I-restricted T cell-
associated molecule (CRTAM) [24], which was identified recently
by our group as a phenotypic marker that is strongly associated
with the activation of Vc9Vd2 PBMCs [25]. Interestingly, after
BrHPP stimulation, CRTAM was found to be expressed similarly
(percentage and MFI) on Vc9Vd2 cells from both LR and R
PBMCs (Fig. 2F and data not shown).
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The Naive Vc9Vd2 Cell Fraction is Reduced in ex vivo LR
EOC PBMCs
The naive and memory subsets of Vc9Vd2 cells were
analyzed in ex vivo LR and R EOC PBMCs according to the
expression of CD27 and CD45-RA markers (Fig. 3). The
median naive cell frequency among Vc9Vd2 PBMCs was
significantly lower in the LR group (37%) than in the R group
(53%; Fig. 3). Accordingly, the median memory cell frequency
was higher in the LR group. Significant positive correlation was
found between the naive cell frequencies among Vc9Vd2
PBMCs and the fold increases of Vc9Vd2 cells after BrHPP
stimulation (p= 0.041 according to the Spearman’s correlation
test). Such correlation was not found in experiments performed
Figure 1. Proliferation of Vc9Vd2 PBMCs from EOC patients and from healthy female donors following BrHPP or zoledronate
stimulation. Vd2+CD3+ cell frequencies among expanded cells (A) and Vd2+CD3+ cell numbers generated from 16106 PBMCs (B) were measured at
14 days after BrHPP (m) or zoledronate (Zol) (&) stimulation. The results from n= 60 patient PBMCs and n= 13 donor PBMCs are shown.
doi:10.1371/journal.pone.0063322.g001
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with Zol. Within the memory compartment, no statistically
significant differences were detected between the LR and R
groups in the frequencies of central, effector or terminally
differentiated effector subsets among Vc9Vd2 PBMCs (Fig. 3).
Thus, no memory Vc9Vd2 subsets were enriched preferentially
in the ex vivo LR EOC PBMCs.
An Imbalance between CD4+CD25highFoxP3high
Regulatory T cells and Vc9Vd2 Cells Exists in ex vivo LR
EOC PBMCs but is Not Involved in the Impaired
Expansion of Vc9Vd2 Cells
The frequencies of CD4+CD25highFoxP3high regulatory T cells
(Tregs) and the ratios of Tregs to Vc9Vd2 cells (Treg:Vc9Vd2
ratio) were explored in ex vivo LR and R EOC PBMCs. The Treg
cell frequencies were not found to be significantly different
between the LR and R EOC PBMCs (Fig. 4A). However,
significant decreases in the Vc9Vd2 cell frequencies in LR EOC
PBMCs led to Treg:Vc9Vd2 ratios that were significantly higher
in the LR group than in the R group (Fig. 4B). Importantly, no
inverse correlations were observed between these ratios and the
fold increases of Vc9Vd2 cells that were measured after
stimulation with either BrHPP or Zol (according to the Spear-
man’s correlation coefficient analyses, p = 0.07 and p= 0.67,
respectively). Additionally, the depletion of Tregs in LR EOC
PBMCs with anti-CD25 microbeads did not improve the
expansion capacities of Vc9Vd2 cells after stimulation with
BrHPP or Zol (Fig. 4C). Indeed, no significant differences were
observed in the frequencies, numbers or fold increases of Vc9Vd2
cells from CD25-depleted LR PBMCs when compared to non-
depleted LR PBMCs after stimulation with either BrHPP or Zol
(Fig. 4C and data not shown). Of note, no depletions of Vc9Vd2
cells and altered cell viabilities were apparent after CD25-
depletion (data not shown). Altogether, these observations suggest
that the increased proportion of Tregs compared to Vc9Vd2 cells
in LR EOC PBMCs is not involved in the impaired response of
Vc9Vd2 cells.
A Reduced Frequency of Vc9Vd2 Cells in ex vivo EOC
PBMCs #0.35% Predicts an Inefficient Response to Both
BrHPP and Zoledronate
An analysis of the ex vivo Vc9Vd2 cell frequencies was then
performed in the four groups previously described in Table 1. The
frequency of Vc9Vd2 cells was significantly reduced in the LR
group when compared to all other groups (Fig. 5A). The median
values of Vc9Vd2 cell frequencies in PBMCs were 0.28% for the
LR group and 1.38% for the R group (Fig. 5A). Intermediate
values were observed for the Br-LR and Zol-LR groups, with
median frequencies of 0.48% and 0.64%, respectively. Interest-
ingly, no significant differences were observed between the LR, Br-
LR, Zol-LR and R EOC groups in the frequencies of non-Vd2+ cd
T cells (Fig. 5B) or of CD3+ cells in PBMCs (Fig. 5C). Besides,
considering the whole cohort, a significant positive correlation was
found between the ex vivo Vc9Vd2 cell frequencies and the fold
increases after stimulation with BrHPP but not with Zol (p = 0.015
according to Spearman’s correlation tests). In addition, positive
correlations between the ex vivo Vc9Vd2 cell frequencies and the
IFN-c-productions in response to either BrHPP or PMA/
ionomycin (measured in Fig. 2C) were evidenced (p = 0.015 and
p,0.001, respectively). These data reveal a specific reduction in
the frequency of the Vc9Vd2 subset that is strongly associated with
functional anomalies in LR EOC PBMCs.
To determine whether a particular Vc9Vd2 cell frequency
value could be used to predict inefficient responses to both BrHPP
and Zol, a receiver-operator characteristic (ROC) analysis was
performed. A Vc9Vd2 cell frequency among PBMCs of 0.35% or
less was always associated with low responses to both BrHPP and
Zol (100% specificity). For frequencies of 0.8% or greater, all the
expansions were efficient with at least one stimuli. For frequencies
between 0.35% and 0.8%, inefficient responses to both stimuli and
efficient responses were observed. These results demonstrate that a
Vc9Vd2 cell frequency of 0.35% or less among ex vivo PBMCs is
predictive of inefficient responses to both BrHPP and Zol.
A Vc9Vd2 Cell Frequency of 0.35% or Less in ex vivo EOC
PBMCs is a Negative Prognostic Marker in EOC Patients
To investigate the relationships between Vc9Vd2 cells and
EOC disease, clinical data from patients were analyzed relative to
the Vc9Vd2 cell frequencies in ex vivo PBMCs (Table 2 and Fig. 5).
Among all the parameters that were recorded at the time of blood
collection, an association was established only with patient age
(Table 2). The median patient age was significantly higher in the
group that had Vc9Vd2 cell frequencies in PBMCs of 0.35% or
less (group#0.35%) than in the group with frequencies greater
than 0.35% (group.0.35%). Importantly, no decreases in the
blood concentrations of leukocytes and PBMCs were observed in
the group#0.35%, which confirms the specific quantitative
deficiency of Vc9Vd2 cells in the peripheral blood. No association
Table 1. Distinct expansions of Vc9Vd2 cells from 60 EOC patients in response to BrHPP and to Zol.
Vd2+ T cell frequency (%) Vd2+ T cell number (6106)
Groups Nb. (%) BrHPP Zol p value
$
BrHPP Zol p value#
All 60 (100) 62+/24 70+/23 0.002 4.5 [1.5–17.5] 5 [2.5–15] 0.473
R 32 (53) 86+/21 86+/21 0.666 14 [6–22.5] 12 [4.5–17] 0.026
Zol-LR 4 (7) 77+/22 56+/24 ,0.001 12.5 [2.5–22.5] 2 [0.5–13] 0.125
Br-LR 8 (13) 38+/27 80+/23 0.015 1.5 [1–3.5] 6 [3–12] 0.015
LR 16 (27) 20+/25 35+/25 ,0.001 0.5 [0–2] 1.5 [0.5–3] 0.022
Vd2+ T cell frequencies in expanded cells (Vd2+CD3+ staining) and Vd2+ T cell numbers generated from 16106 PBMCs were measured 14 days after BrHPP or zoledronate
(Zol) stimulation; data are presented as means +/2 SEM or medians with [first quartile - third quartile]; The Vd2+ T cell frequency of 70% and the Vd2+ T cell number of
26106 (corresponding to the mean of the first quartile values of expanded Vd2+ T cell number with BrHPP and with Zol) were both used as cut-off values to distinguish
efficient expansions ($70% and $26106 cells) from inefficient expansions (,70% or ,26106 cells); four PBMC groups were distinguished: R, Zol-LR, Br-LR and LR; Nb.
(%) denotes the number of samples and the corresponding percentage; BrHPP and Zol data were compared using
$
paired t-test or #wilcoxon matched pairs test; p
value ,0.05 indicates a significant difference.
doi:10.1371/journal.pone.0063322.t001
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was established between this deficiency and the administration of
chemotherapy prior to blood collection. Moreover, no correlation
was found between the deficiency in peripheral blood Vc9Vd2
cells and an advanced stage of disease or higher tumor grade. With
regard to the treatment of EOC patients (Table 2), no significant
differences were observed between the group#0.35% and the
group.0.35% in the efficacy of debulking surgery or in the type of
received chemotherapy (Table 2). However, the clinical outcomes
of chemotherapy-treated EOC patients were found to be distinct
between the groups. Interestingly, the proportion of patients who
were refractory to chemotherapy was significantly higher in the
group#0.35% (62.5%) than in the group.0.35% (17.5%)
(Table 2). In addition, univariate analyses of disease-free survival
with different relevant factors revealed that a Vc9Vd2 cell
frequency of 0.35% or less in PBMCs and a non-optimal
debulking are predictors of shorter disease-free survival duration
(Table 3). With an average follow-up duration of 13 months for
these patients, the median duration of disease-free survival was 1
month in the group#0.35% versus 10 months in the
group.0.35% (Fig. 5). Importantly, the negative prognostic value
of the reduced Vc9Vd2 cell frequency was maintained after an
adjustment in a multivariate analysis (Table 3).
Discussion
Previous studies have shown that conventional ex vivo Vc9Vd2
cell expansion protocols based on the stimulation of PBMCs with
Figure 2. Reduced functionality of Vc9Vd2 cells in LR EOC PBMCs without defects in expression level of CD3f and CRTAM
molecules. A, B) Vd2+CD3+ cell fold increases in LR (n = 16) and R (n = 32) EOC PBMCs at 14 days after BrHPP (A) or Zol (B) stimulation. C)
Percentages of IFN-c+ cells in the Vd2+CD3+ cells measured at 5 h after the stimulation of ex vivo LR (n = 10) and R (n = 10) PBMCs with BrHPP (3 mM)
or PMA/ionomycin (PMA/iono). D) Percentages of IFN-c+ cells (left panel) and TNF-a+ cells (right panel) among the Vd2+CD3+ cells measured at 5 h
after stimulations of ex vivo LR (n = 4) and R (n = 4) PBMCs with increasing doses of BrHPP (0.1 to 6 mM). E) Expression of the CD3f chain measured on
Vc9Vd2 PBMCs from the LR and R groups. Percentage (upper panel) and MFI (lower panel) of CD3f staining in the Vd2+CD3+ cells from LR EOC PBMCs
(n = 5), R EOC PBMCs (n = 3) and R donor PBMCs (n = 3). F) CRTAM expression on Vc9Vd2 cells measured at 20 h after stimulation of LR (n = 8) and R
(n = 8) EOC PBMCs with BrHPP. No stim: no stimulation.
doi:10.1371/journal.pone.0063322.g002
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BrHPP or Zol failed in an average of 35% of cancer patients
[12,20–22,26,27]. Here, we confirmed these observations in EOC.
From 60 EOC PBMC samples, inefficient expansions after
stimulation with either BrHPP or Zol occurred in 40% and 33%
of cases, respectively. Interestingly, our comparative analyses also
revealed that BrHPP and Zol differed in their capacities to expand
Vc9Vd2 PBMCs from patients. Samples that were not efficiently
expanded with BrHPP could be efficiently expanded with Zol, and
the reverse was also true. These results suggest that each
compound might be tested in small-scale expansion assays to
allow for the choice of the best compound for each patient.
Nevertheless, 27% of PBMC samples from EOC patients
remained inefficiently expanded with both compounds (LR
PBMCs). We showed that the Vc9Vd2 cells in these ex vivo LR
PBMCs not only had reduced proliferative capacities but also
displayed an altered production of pro-inflammatory cytokines
IFN-c and TNF-a ?compared to the Vc9Vd2 cells from
responding (R) PBMCs. Saturating doses of BrHPP failed to
restore the response of Vc9Vd2 cells in LR PBMCs. These results
support an intrinsic functional defect of LR Vc9Vd2 PBMCs and
suggest that the use of higher doses of phosphoantigens to improve
response of Vc9Vd2 cells in LR EOC PBMCs would be
unsuccessful. To our knowledge, this is the first ex vivo demonstra-
tion of altered Vc9Vd2 cell effector functions in EOC patients.
Many parameters could be related to this reduced functionality.
The loss or reduced expression of the CD3f chain on T cells from
cancer patients has been implicated in impaired T cell activation
[28]. However, no differences were observed in CD3f chain
expression on ex vivo Vc9Vd2 cells between the LR and R PBMCs
in our EOC cohort, which indicates that the expression of this
chain is not causative. Defects in expression of activation markers
could also be associated. Here, the molecule CRTAM, recently
described by our group as a phenotypic marker that is strongly
related with the activation of Vc9Vd2 PBMCs [25], was found to
be expressed similarly on Vc9Vd2 cells from both LR and R EOC
PBMCs after BrHPP stimulation. This observation suggests that
signaling events leading to CRTAM expression are not defective
in Vc9Vd2 from LR PBMCs. Besides, the presence of
CD4+CD25highFoxP3high T regulatory cells (Tregs) could be
involved in the Vc9Vd2 cell deficiencies in cancer patients [29].
Recent data from Kunzmann et al. have documented that an
increase in the Treg:Vc9Vd2 ratio suppressed phosphoantigen-
induced cd T cell proliferation and contributed to the state of
apparent immunological unresponsiveness to phosphoantigens
that was observed in some cancer patients [27]. Our results in
EOC patients showed an increased Treg:Vc9Vd2 ratio in ex vivo
LR PBMCs. However, we did not find an inverse correlation
between this ratio and the fold increases of Vc9Vd2 cells in
response to either BrHPP or Zol. Moreover, Kunzmann et al. have
reported that the depletion of Tregs (using CD25-depletion) in
low-responding PBMCs from patients with tumors others than
EOC restored Vc9Vd2 cell expansion in response to phosphoanti-
gens. Here, the same cell depletion in LR PBMCs from EOC
patients did not improve the proliferation of Vc9Vd2 cells in
response to phosphoantigens or aminobisphosphonates. In addi-
tional assays, we tested an oblique method of cell depletion to
remove Tregs from LR EOC PBMCs while preserving CD25+
activated cells with the use of the CD4+CD25+CD127dim/2
Regulatory T Cell Isolation Kit II from Miltenyi Biotec (data not
shown). Interestingly, effects of such depletion on the proliferation
of Vc9Vd2 cells were similar to those observed with the CD25-
depletion. All together, these results indicate that Tregs are not
involved in the impaired proliferation of Vc9Vd2 cells in EOC.
Alternatively, differences in the ex vivo proportions of naive and
memory Vc9Vd2 cell subsets could be associated with the reduced
functionality of Vc9Vd2 EOC PBMCs, as it has been observed in
other cancers [12,21,22]. Herein, we found that the naive subset
was significantly reduced in ex vivo LR EOC PBMCs. This
decrease might have been triggered by the repeated antigen
priming of Vc9Vd2 cells in vivo during the development of the
disease and with age, leading to a marked differentiation of naive
cells to the memory cell compartment in some patients. The
Figure 3. A reduced naive Vc9Vd2 subset in ex vivo LR EOC PBMCs. Percentages of naive (CD27+CD45RA+), central memory (CM)
(CD27+CD45RA2), effector memory (EM) (CD272CD45RA2) and terminally differentiated effector memory (TEMRA) (CD272CD45RA+) cells among the
Vd2+CD3+ cells in ex vivo LR (n = 13) and R (n = 11) EOC PBMCs.
doi:10.1371/journal.pone.0063322.g003
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Vc9Vd2 cell frequencies in ex vivo PBMCs from patients could also
be related to inefficient Vc9Vd2 cell expansions. Data from the
literature on this issue are diverging. A correlation between the
baseline percentages of Vc9Vd2 cells in PBMCs from different
cancer patients and the ex vivo expansion capacities has been
established recently [12], while another previous study reported no
association between the same parameters in a large cohort of
patients with different types of cancer [27]. Our study of EOC
patients supports the most recent observation of specifically
reduced Vc9Vd2 cell frequencies in ex vivo LR PBMCs. These
deficiencies in Vc9Vd2 PBMCs, combined with decreases in
proportion of the naive subset that is endowed with proliferative
capacities [30], might be partly responsible for the reductions in
Vc9Vd2 cell proliferation that were observed in some LR EOC
Figure 4. An imbalanced ratio of Tregs and Vc9Vd2 cells in ex vivo LR EOC PBMCs. A) CD4+CD25highFoxP3high cell (Treg) frequencies and
corresponding Vd2+CD3+ cell frequencies in ex vivo LR (n = 13) and R (n = 11) PBMCs. B) The ratios of Tregs (%) to Vd2+CD3+ cells (%) (Treg:Vd2+ ratio)
among PBMCs in the LR and R groups. C) LR PBMCs from EOC patients (n = 6) were stimulated with BrHPP (m) or Zol (&) and IL-2 before and after the
depletion of CD25+ cells; the proliferation of Vd2+CD3+ cells was analyzed on day 7. Vd2+CD3+ cell frequencies among expanded cells (left panel) and
Vd2+CD3+ cell fold increases (right panel) are shown.
doi:10.1371/journal.pone.0063322.g004
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PBMCs. Of note, the peripheral blood Vc9Vd2 cell frequencies in
EOC patients were not affected by chemotherapy and we
confirmed an age-dependent decrease of Vc9Vd2 cell frequencies
in EOC patients, as was observed by other authors in healthy
subjects [31,32]. Importantly, we demonstrated that a Vc9Vd2
cell frequency among ex vivo PBMCs from EOC patients of 0.35%
or less was always associated with inefficient expansions in
response to BrHPP and to Zol. These data identify the Vc9Vd2
cell frequency in PBMCs of 0.35% or less as a unique biomarker
that might be useful for the prediction of inefficient expansions of
PBMCs from EOC patients in response to both conventional
BrHPP- or Zol-based cd expansion protocols.
Another important point addressed in this study was the
relationships between Vc9Vd2 cells and the clinical outcomes of
EOC patients who were treated with surgery plus platinum-based
chemotherapy. Platinum derivatives have been described as
immunomodulatory compounds, and candidate immune biomark-
ers such as ab T cells have already been implicated in the efficacy
of these anticancer agents [33,34]. Two studies in human
advanced ovarian carcinoma have reported that the presence of
tumor-infiltrating CD3+ T cells is correlated with improved
clinical outcomes of patients who were treated with surgery plus
platinum-based chemotherapy [35,36]. Of these two studies, one
has also reported a correlation between the presence of infiltrating
cd T cells and a brief disease-free interval after treatment [36].
However, this study, which was based on a molecular assessment
of TCRc by PCR analysis, did not discriminate between Vc9Vd2
and other cd cells. Here, we demonstrate that EOC patients with a
decreased peripheral blood Vc9Vd2 cell frequency of 0.35% or
less, which is correlated strongly with an impaired Vc9Vd2 PBMC
functional profile, are more likely to be refractory to platinum-
based chemotherapy and display a shorter disease-free survival
time after treatment. A multivariate analysis confirms that this
reduced frequency is an independent predictor for disease-free
survival time. Therefore, the Vc9Vd2 cell frequency in PBMCs
could be used as a prognostic biomarker in EOC patients. Taken
together, our observations support the conclusion that the
outcomes for chemotherapy-treated patients are more favorable
when there are no deficiencies in the numbers and functionality of
peripheral blood Vc9Vd2 cells. Interestingly, these data are the
first to suggest that the Vc9Vd2 cell subset could contribute to the
anti-tumor effects of conventional anticancer chemotherapeutics.
In conclusion, our results indicate that a specific Vc9Vd2 cell
frequency value in ex vivo PBMCs could be used to select eligible
EOC patients for conventional BrHPP- or Zol-based cd expansion
protocols and to predict the clinical outcomes for chemotherapy-
treated EOC patients. The data suggest that the combination of
current chemotherapeutic treatments in EOC with Vc9Vd2 cell-
based immunotherapies could have a clinical interest for patients
and should be explored. Our data also reveal that EOC patients
with the worst prognostic outcomes are those with inefficient
Vc9Vd2 PBMC expansions to both conventional BrHPP- or Zol-
based cd expansion protocols. Fortunately, other strategies that
could increase Vc9Vd2 cells in these patients are conceivable. A
powerful expansion protocol using aminobisphosphonates-pre-
treated dendritic cells or the transfer of allogenic Vc9Vd2 cells
from healthy donors could represent alternative solutions [20].
Materials and Methods
Ethics Statement
This paper contains experiments using human cells. The paper
satisfies PLOS ONE policies regarding human subject research.
The Centre de Ressources Biologiques (CRB) from CHU of
Rennes approved this study. The study was agreed by the french
ministery of research and recorded under the nu"DC 2008-738".
Written informed consent was obtained from all participating
subjects.
Cells from Donors and EOC Patients
PBMCs were isolated from peripheral blood samples from
healthy female donors (Do#, n = 13 from the Etablissement
Franc¸ais du Sang, Villejean, Rennes, France) and patients with
epithelial ovarian adenocarcinoma (EOC) (O#; n = 59 from the
Gynecology Department, CHU of Rennes, France; n= 1 from
Surgical Oncology, ICO-Cancer Center, Nantes; France) by the
density separation method (UnisepH, Novamed, Jerusalem, Israel).
Blood samples from EOC patients were collected before (n = 46)
Figure 5. Specific quantitative deficiencies of Vc9Vd2 cells in ex vivo LR EOC PBMCs. Frequencies of Vd2+CD3+ cells (A), Vd22cd+CD3+ cells
(B) and CD3+ cells (C) among LR (n = 16), Br-LR (n = 8), Zol-LR (n = 4) and R (n = 32) EOC PBMCs are shown. Differences between LR group and each of
other groups are indicated. A) A receiver-operator characteristic (ROC) analysis was performed in which LR PBMC samples were compared to the
other PBMC samples. Dashed lines indicate cut-offs at 0.35% and 0.8%. Sp: Specificity. Se: sensibility.
doi:10.1371/journal.pone.0063322.g005
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and after (n = 14) chemotherapeutic treatment. The mean age of
the patients was 63.9 years (6SEM 1.5). Serous-papillary,
endometrioid, mucinous and clear cell adenocarcinoma histolog-
ical types were diagnosed anatomopathologically in 43, 10, 3 and
4 cases, respectively. Grades I, II, and III were noted in 11%, 31%
and 58% of cases, respectively. The EOC staging was performed
according to the International Federation of Gynecology and
Obstetrics (FIGO) classification system [37]. The majority of the
patients had advanced disease; 56.7% and 15% had FIGO stage
disease III and IV, respectively, and 10% were in relapse. All
patients underwent a surgical procedure. Platinum derivative-
based chemotherapy was also performed for 52/60 patients.
Carboplatin, carboplatin-taxol and gemcitabine-oxaliplatin agents
were used in 7, 44 and 1 cases, respectively. Optimal debulking
with surgery was defined by the absence of residual individual
tumor nodules after surgery. A state refractory to chemotherapy
was defined by increases in tumor size and/or CA-125 values at
the end of the chemotherapy treatment. Refractory states were
reported in 25% of the cases. The duration of disease-free survival
was measured as the time between the end of treatment (surgery
plus chemotherapy) and the first disease recurrence or progression.
The duration of overall survival was calculated as the time
between the end of treatment and death. Data were censored at
the final follow-up for patients without disease recurrence,
progression or death. The follow-up duration was defined as the
time between the end of treatment and either death or the final
follow-up.
Antibodies and Reagents
Monoclonal antibodies (mAbs) against the following antigens
were used for staining: Vd2 (IMMU389), pan-cd (IMMU510),
CD45RA (ALB11), CD3 (CD3e; UCHT1), CD3f (2H2D9), CD4
(13B8.2), CD14 (RMO52) and CD25 (B1.49.9) were obtained
Table 2. Clinical characteristics of EOC patients according to their Vd2+ T cell frequency in PBMCs.
#0.35% .0.35% p value ¥
n=11 n=49
At blood collection Tumor histological type SP 7 (64) 36 (73.5) 0.712
E 2 (18) 8 (16.5) 1.000
M 2 (18) 1 (2) 0.084
CC 0 (0) 4(8) 1.000
Tumor grade I 2 (20) 4 (9) 0.297
II 5 (50) 12 (27) 0.254
III 3 (30) 29 (64) 0.075
nd 1 4
FIGO stage I and II 2 (18) 9 (18.5) 1.000
III 7 (64) 27 (55) 0.742
IV 0 (0) 9 (18.5) 0.188
recurrence 2 (18) 4 (8) 0.302
Ca125 (UI/ml) median [2] 203 [52–1042] 451 [51–1850] 0.607
Leucocytes (GIGA/L) median [2] 9.1 [5.6–10.4] 8.0 [6.3–10.3] 1.000
PBMCs (GIGA/L) median [2] 1.4 [0.9–2.4] 1.5 [0.9–1.9] 0.573
Blood punction after chemo 4 (36) 9 (18) 0.231
Age (years) median [2] 76 [70–78] 62 [54–71] 0.003
Treatment Optimal debulking yes 6 (60) 25 (62.5) 1.000
no 4 (40) 15 (37.5)
nd 1 9
Platinum-based chemotherapy received 9 (82) 43 (88) 0.630
Carboplatin 2 (22) 5 (12) 0.590
Carboplatin- taxol 6(67) 38 (88) 0.130
Gemcitabine-oxaliplatin 1 (11) 0 (0) 0.173
Refractory to chemotherapy no 3 (37.5) 33 (82.5) 0.016
yes 5 (62.5) 7 (17.5)
nd 1 3
Patients with Vd2+ T cell frequencies in PBMCs of 0.35% or less (#0.35%) (n = 11) or greater than 0.35% (.0.35%) (n = 49) at the time of blood collection. Tumor
histological type (serous-papillary (SP), endometrioid (E), mucinous (M), clear cell (CC)), tumor grade, FIGO stage, Ca125 concentration, leucocyte concentration, PBMC
concentration and patient age at time of blood punction are indicated; PBMC samples collected after chemotherapy are noticed; the optimal debulking of tumor after
surgery (no residual tumor nodules), the number of patients who received chemotherapy, the type of chemotherapy and the numbers of patients who were refractory
to chemotherapy are indicated; data are presented as medians [first quartile – third quartile] for continuous variable and as numbers (with corresponding percentages)
for qualitative variables; nd denotes case not determined;
¥ continuous variables were compared using the Mann-Whitney test and categorical variables using the Fisher’s exact test; p value ,0.05 indicates a significant
difference.
doi:10.1371/journal.pone.0063322.t002
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from Beckman Coulter (Villepinte, France); CD27 (o323) and
Foxp3 (236A/E7) were obtained from eBioscience (Paris, France);
CRTAM (210213) was obtained from R&D systems (Lille,
France); and IFN-c (B27) and TNF-a (MAb11) were obtained
from BD Biosciences (Le Pont de Claix, France). Isotype-matched
mAbs (Beckman Coulter, eBioscience, R&D systems or BD
Biosciences) were used as staining controls. Synthetic BrHPP
(PhosphostimTM) was kindly provided by Innate Pharma (Mar-
seille, France). Synthetic Zoledronate (ZometaH) was obtained
from Novartis (Rueil-Malmaison, France). Recombinant human
IL-2 (ProleukinH) was obtained from Chiron Therapeutics
(Suresnes, France). Monensin, saponin, PMA and ionomycin were
purchased from Sigma Aldrich (Saint-Quentin Fallavier, France).
Vc9Vd2 Cell Expansion Assay
Ex vivo PBMCs were resuspended at 1.26106 cells/ml in RPMI
1640 medium (Eurobio, Les Ullis, France) that was supplemented
with 10% fetal calf serum (FCS) (Gibco Invitrogen Life
Technologies, Cergy Pontoise, France), 2 mM L-glutamine,
100 mg/mL streptomycin and 100 U/mL penicillin (hereafter
referred to as RPMI-FCS) and were specifically activated with
3 mM BrHPP or 1 mM zoledronate plus 400 UI/ml recombinant
IL-2. Cultures were maintained at 37uC for two weeks at 0.56106
cells/mL in RPMI-FCS plus 400 UI/ml IL-2. The concentrations
of BrHPP, zoledronate and IL-2 that were used in this study were
defined in accordance to clinical protocols [6,12] and dose-scaling
studies that ranged from 0.3 to 30 mM for BrHPP, from 1 to
10 mM for zoledronate and from 400 UI/ml to 3200 UI/ml for
IL-2 (laboratory data). Vc9Vd2 cell specific expansion was
measured by calculating the frequencies of Vd2+CD3+ cells and
the absolute Vd2+CD3+ cell numbers at day 0 among PBMCs and
at day 14 among expanded cells. The fold increases of Vc9Vd2
cells at day 14 were calculated according to the following formula:
fold increase = (absolute Vd2+CD3+ cell number at day 14)/
(absolute Vd2+CD3+ cell number at day 0).
Depletion of CD25+ Cells and Vc9Vd2 Cell Proliferation
Assay
Ex vivo PBMCs were depleted of CD25+ cells by a magnetic cell
separation with CD25 microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions.
The efficacy of CD25 depletion in PBMCs and the frequency of
Vd2+CD3+ cells in depleted-PBMCs were evaluated by flow
cytometric analysis. Next, CD25+-depleted PBMCs and non-
Table 3. Regression analyses of disease-free survival in surgery plus chemotherapy-treated patients.
Univariate analysis Mutivariate analysis W
Variables Nb HR 95% CI p value Nb HR 95% CI p value
Vd2+ T cells in PBMC (%)
#0.35 9 2.30 1.03 to 5.13 0.042 8 2.99 1.22 to 7.29 0.016
.0.35 43 43
Histologic type NI
CC 4 1.71 0.52 to 5.59 0.378
SP, E or M 48
Tumour gradea NI
1 4 0.51 0.11 to 2.19 0.367
2 15 1.28 0.62 to 2.64 0.496
3 29
FIGO stage NI
I or II 6 0.00 0 to 39.5E+168 0.947
III 32 1.15 0.39 to 3.30 0.800
IV 9 1.50 0.44 to 5.11 0.513
Relapse 5
Optimal debulkingb
no (.1 cm) 26 2.50 1.22 to 5.11 0.012 26 2.93 1.39 to 6.17 0.005
yes (#1 cm) 25 25
Platinum-based chemotherapy NI
without taxol 8 1.50 0.62 to 3.63 0.366
with taxol 44
Age (years) NI
$70 21 1.20 0.61 to 2.35 0.596
,70 31
Results obtained using the Cox proportionnal hazard regression model; Nb denotes number of patients; HR denotes Hazard Ratio; CI denotes confidence interval;
Tumor histological type (serous-papillary (SP), endometrioid (E), mucinous (M), clear cell (CC);
adata available in 48 patients;
bdata available in 51 patients;
Wmultivariate analysis with data available in 51 patients : variables found to have a p value ,0.1 in the univariate analysis were included in the model; NI denotes not
included; p value ,0.05 indicates a significant difference.
doi:10.1371/journal.pone.0063322.t003
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depleted PBMCs from the same patients were resuspended at
1.26106 cells/ml in RPMI-FCS with 400 UI/ml IL-2 (0.66106
cells per well of a 48-well plate). The cells were stimulated by the
addition of 3 mM BrHPP or 1 mM zoledronate and were
incubated at 37uC for 7 days. At day 4, 0.25 ml of RPMI-FCS
with IL-2 (400 UI/ml) was added to each well. The frequencies,
numbers and fold increases of Vc9Vd2 cells at day 7 were
measured as described previously.
IFN-c and TNF-a Responses and CRTAM Expression Assay
Ex vivo PBMCs were activated at 37uC in RPMI-FCS (1.26106
cells/ml) by the addition of BrHPP (0.1 to 30 mM) or PMA
(20 ng/ml) plus ionomycin (0.5 mM). To measure IFN-c and
TNF-a responses, intracellular cytokine accumulation was induced
by the addition of 3 mMmonensin after 1 h of activation. The cells
were collected 4 h later, stained for Vd2 TCR chain and CD3
expression, and fixed with 1% formol. Fixation was followed by
permeabilization with 0.5% saponin for 20 min and incubation
with IFN-c-specific or TNF-a specific mAbs for 30 min. To
measure CRTAM expression, cells were collected 20 h after
activation, stained for Vd2 TCR chain, CD3 and CRTAM
expression and fixed with 1% formol.
Flow Cytometry and Statistical Analysis
Stained cells were analyzed by flow cytometry with a
FACSCalibur system (BD Biosciences) and FlowJo software (Tree
Star, Ashland, OR, USA). Statistical analyses were performed with
GraphPad Prism 5.0 (La Jolla, CA, USA) and Sigma plot 12.0
softwares (San Jose, CA, USA). The column scatter plots all show
lines drawn at the medians. Comparison tests between groups
were performed using Mann-Whitney U tests in Fig. 1, Fig. 2 (A,
B, C, E and F), Fig. 3, Fig. 4 (A and B) and Fig. 5; a two-way
ANOVA in Fig. 2D; a wilcoxon matched pairs test in Fig. 4C; and
a log-rank (Mantel-Cox) test in Fig. 6. *, ** and *** indicate
statistically significant differences for which p,0.05, p,0.01 and
p,0.001, respectively. ns indicates that the difference was not
significant.
Supporting Information
Figure S1 Reduced IFN-c and TNF-a responses of
Vc9Vd2 cells in LR EOC PBMCs. Percentages of IFN-c+
cells and TNF-a+ cells among the Vd2+CD3+ cells measured at
5 h after stimulation of ex vivo LR and R EOC PBMCs with
increasing doses of BrHPP (n= 3). Comparison tests between
groups were performed using a two-way ANOVA. *** indicates
statistically significant differences for which p,0.001.
(TIF)
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